OSAM
SYRE icon

O'Shaughnessy Asset Management’s Spyre Therapeutics SYRE Stock Holding History

O'Shaughnessy Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-66
Closed -$12K – 2850
2021
Q2 		$12K Hold
66
– – ﹤0.01% 1971
2021
Q1 		$13K Hold
66
– – ﹤0.01% 1734
2020
Q4 		$13K Buy
+66
New +$13.7K ﹤0.01% 1500

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

O'Shaughnessy Asset Management's SYRE Position: Q3 2021 in Review

O'Shaughnessy Asset Management sold out of Spyre Therapeutics (SYRE) in Q3 2021, closing a stake of 66 shares — an estimated $12K sold.

O'Shaughnessy Asset Management first reported a position in SYRE in Q4 2020 and held it in 3 quarters. The position peaked at $13K in Q1 2021. 77 funds tracked by Wall St. Rank hold SYRE as of Q3 2021.

  • O'Shaughnessy Asset Management reported no remaining Spyre Therapeutics position as of Q3 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 66 Spyre Therapeutics shares in Q3 2021, an estimated $12K.
  • O'Shaughnessy Asset Management first reported a position in Spyre Therapeutics in Q4 2020 and held it in 3 quarters.
  • O'Shaughnessy Asset Management's Spyre Therapeutics position peaked at $13K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.